Peptides: The Access Fight

This page chronicles a live policy fight inside Secretary Kennedy's HHS. It is not medical advice: it names no doses, no protocols, and no sources for any compound, and it takes no position on whether any peptide works. What it documents is who is deciding, what the evidence actually shows, and who is selling what. Status as of October 18, 2026 — this file is moving, and this page is date-stamped accordingly.

Where things stand today

One fact organizes everything else: as of October 18, 2026, none of the contested peptides — BPC-157, TB-500, MOTS-c, the rest — is FDA-approved, and none is lawfully compoundable under section 503A. Legal analysts across firms (McDermott, Holland & Knight, Frier Levitt, Sheppard Mullin) agree on the distinctions the headlines blur: removal from Category 2 is not placement in Category 1, is not a spot on the 503A Bulks List, and is not approval.

The narrow exceptions: GHK-Cu in non-injectable form and VIP sit in Category 1 (compoundable under enforcement discretion), and sermorelin is lawfully compoundable because it was once an FDA-approved drug (Geref, 1997; discontinued in 2008 for commercial reasons, not safety). Everything else in the boom runs through cash-pay clinics operating in the gray, telehealth, or the outright black market described below.

How we got here

• Sept 29, 2023 — The Biden-era FDA places 19 substances in 503A Category 2 (compounding barred): BPC-157, TB-500, CJC-1295, ipamorelin, injectable GHK-Cu, MOTS-c, MK-677, kisspeptin-10, thymosin alpha-1, and others, citing immunogenicity, impurity, and thin human data concerns.
• Late 2024 — Five substances quietly exit Category 2 when their nominations are withdrawn; the then-PCAC votes against every peptide put to it.
• Feb 27, 2026 — Secretary Kennedy, on Joe Rogan’s podcast, calls himself a peptide user and signals roughly 14 of the 19 will move back toward Category 1. A statement — not a regulatory act.
• April 15, 2026 — FDA removes 12 substances from Category 2, stating in every case the same reason: the nominations were withdrawn — not a safety finding. The compounds land in limbo: no longer barred as Category 2, still not compoundable. (One unresolved discrepancy: FDA’s May 2026 category document reportedly still lists ibutamoren and kisspeptin-10 in Category 2. We flag it rather than resolve it.)
• June 29, 2026 — FDA staff recommend against all seven newly nominated peptides. The same day, a reconstituted advisory committee (PCAC) is announced with eight new permanent members; AP and the New York Times report that six of the eight run or work for clinics or pharmacies that sell peptides. HHS says all passed standard ethics review; UC Davis’s Paul Knoepfler told the Washington Post, “It seems RFK Jr. stacked the committee.”
• July 23–24, 2026 — The PCAC votes to recommend 6 of 7 for the Bulks List, over unanimous FDA staff opposition: BPC-157 (8–6), KPV (8–6), TB-500 (8–6), MOTS-c (7–5), epitalon (7–4), semax (8–5); DSIP is rejected (6–7). Clinician Elizabeth Yurth testified for access. A second panel, covering injectable GHK-Cu, dihexa, LL-37, melanotan II, and PEG-MGF, is expected before February 2027.
• October 2026 — The live frontier: the Washington Post (Oct 7) reported an administration “stopgap” to allow temporary compounding; the Pink Sheet (Oct 8) reported CDER staff would not recommend it; on Oct 14, HHS/FDA submitted an “Interim Access Policy for Compounding Using Certain Peptides” to White House/OMB review (Reuters, Oct 15) — contents undisclosed, not yet issued, and its legality already contested. The same day, CSPI’s Dr. Peter Lurie formally urged Acting Commissioner Kyle Diamantas to overrule the panel. Formal rulemaking is estimated at a late-2026/2027 proposal with a final rule possibly in 2027–2028.

Congress is pressing from the side: Rep. Diana Harshbarger (R-TN) wrote Kennedy in November 2025 urging enforcement discretion for six peptides; her son, State Sen. Bobby Harshbarger, sits on the new PCAC. And the states are splitting — Ohio has suspended 30+ clinics since early 2025 and Alabama’s medical board barred physicians from non-approved peptides outright in June 2026, while Texas, Florida, Nevada, and Arizona sit at the federal floor. A federal win for compounders would not override the strict states.

The evidence argument, both sides as they make it

The critics’ case (attributed): For BPC-157, a 2025 systematic review in the American Journal of Sports Medicine screened 544 papers and found 36 — 35 preclinical, one clinical study (a 12-patient retrospective); the one registered Phase I trial never published results. USADA (Aug 2026): “no human clinical trials establishing efficacy… for any diagnosis.” TB-500 has zero human trials of the fragment. McGill’s Jonathan Jarry notes BPC-157 was studied “almost exclusively by the same Croatian team that created it.” Yale’s Reshma Ramachandran argues the incentives “aren’t actually centered around patients. They’re centered around selling products.” Eric Topol warns expanded access makes definitive trials less likely to ever be run. Physician Gabrielle Lyon — herself inside the performance-medicine world — calls the April 2026 removal “policy pressure, not new safety data.”

The access case (attributed): The clinicians who testified — Yurth; endocrinologist Edwin Lee, who founded the Save Peptides petition drive — argue the compounds were removed without safety findings, that patients are already using them, and that supervised pharmacy access beats the alternative. The compounding industry’s Scott Brunner (APC) and clinician Rachel Strauss (to AJMC) make the structural version: banning demand won’t eliminate demand — “it’s just pushing patients towards more shady places.”

Athletes, note: WADA bans BPC-157 (S0) and TB-500, ipamorelin, CJC-1295, sermorelin, and MK-677 (S2). A prescription is no defense in tested sport.

The gray market underneath it

While the committee process grinds, the unregulated market is the actual supply chain for most users — and it is documented, not rumored:

• FDA warning-letter waves against “research use only” sellers (Dec 2024; Feb 2025; five more on Aug 24, 2026). The agency rejects the RUO disclaimer outright: dosing guides, calculators, and selling bacteriostatic water are treated as evidence of intended human use.
• U.S. v. Matthew Kawa (Paradigm Peptides): sentenced July 2026 to 70 months plus $5M forfeiture — ~54,000 customers, forged certificates of analysis, and “testosterone-mimic” products that actually contained steroids, sold after two prior FDA warning letters.
• CBP seizures: ~130,000 vials intercepted nationally between October 2025 and August 2026. Peptide Sciences, described as the largest gray-market vendor, shut down March 6, 2026. A Utah physician was indicted in April 2026 (an allegation, no verdict) over Chinese-sourced compounds sold to 200+ patients.
• Documented harms exist alongside the access argument: two women intubated after injections at a Las Vegas longevity-conference booth in July 2025 (cause undetermined; Nevada’s pharmacy board fined four parties); KFF (Oct 13, 2026) reports users describing prolonged fatigue, anxiety, and anhedonia after BPC-157 bought online, plus FDA adverse-event hospitalizations. Harvard’s S. Bryn Austin asks the question the market cannot answer: “What else is in that vial?”

Our sister site AllegedFraud tracks the fraud side of this market case by case.

The people this site tracks on peptides

• Elizabeth Yurth, MD — the clinician who testified for access at the July 2026 PCAC.
• Edwin Lee, MD — endocrinologist; founder of Save Peptides; the access campaign’s organizer.
• Gabrielle Lyon, DO — the credentialed critic inside the performance-medicine world.
• Brigham Buhler — owns the clinic and the pharmacy; the industry inside the movement (conflicts disclosed on his profile).
• Gary Brecka — the largest influencer channel pushing peptide stacks to the MAHA audience (seller-adjacent; disclosed).
• Jillian Michaels — already on the roster; her warnings target gray-market self-dosing specifically. See her position on imported peptide supplements and her peptide-safety initiative page.
• Kyle Diamantas — Acting FDA Commissioner; the man who owns the pending decision.

This page will be updated as the OMB review, the second PCAC, and the rulemaking move. Every factual claim above is tied to the dated sourcing in our research file.